Elisabet de los Pinos, President and CEO of Aura Biosciences (NASDAQ:AURA), recently sold 15,955 shares of the company, valued at approximately $122,381. The biotech company, currently valued at $388 million, maintains a "FAIR" financial health score according to InvestingPro analysis. The shares were sold at a weighted average price of $7.67, with transactions occurring between $7.67 and $7.72 per share. Following the sale, de los Pinos holds 304,692 shares directly, with an additional 131,412 shares held indirectly through the Elisabet de los Pinos Revocable Trust. The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units and was not discretionary. While the company faces profitability challenges, analysts maintain optimistic price targets ranging from $20 to $23 per share. InvestingPro subscribers can access additional insights about AURA's financial health and growth prospects, including 6 key ProTips.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.